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Abstract: Memantine is a low to moderate afﬁ  nity N-methyl-D-aspartate receptor (NMDAR) 
antagonist. The effects of memantine in Alzheimer’s disease (AD) have been studied in 7 random-
ized controlled trials in many post-hoc analyses. Three out of four RCTs in patients with moderate 
to severe AD (Mini Mental State Examination [MMSE]  14) showed a statistically signiﬁ  cant 
but clinically small positive effect of memantine on cognition, global functioning, activities 
of daily living (ADL) and neuropsychiatric symptoms. No effects on these outcome measures 
could be found in the three RCTs studying patients with mild to moderate AD (MMSE 14–24). 
Two of these studies evaluated the effect of addition of memantine to donepezil. Only the study 
in patients with mild to moderate AD showed a positive effect of addition of memantine on 
cognition, ADL, global functioning and neuropsychiatric functioning. Cost-effectiveness of 
memantine therapy remains controversial. Post-hoc analyses and observational studies suggest 
some effects on agitation/aggression, delusions or hallucinations. Side effects of memantine are 
usually mild and seem to be comparable with placebo. In this review, an oversight of pharma-
codynamics and pharmacokinetics of memantine is presented. Also, published data concerning 
efﬁ  cacy and safety in patients with AD are presented.
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Introduction
Memantine is a low to moderate afﬁ  nity N-methyl-D-aspartate receptor (NMDAR) 
antagonist that was approved as a therapeutic drug in moderate to severe Alzheimer’s 
disease (AD) in 2002 by the European Agency for the Evaluation of Medicinal Prod-
ucts (EMEA), followed in 2003 by the USA Food and Drug Administration (FDA). 
Despite this relatively recent approval for AD, memantine is not a new drug. Eli Lilly 
synthesized it in the early sixties as a drug for the treatment of diabetes mellitus.1 In 
the 1980s, it was studied as a drug for various neurological diseases (eg, Parkinson’s 
disease, neurogenic bladder disorders, coma). In 1986, the ﬁ  rst report of the use of 
memantine (intravenous) in patients with AD was published.2 In this small (n = 20) 
and probably underpowered study, no positive effects of memantine could be found 
on several measures of global and neuropsychiatric functioning. More than 10 years 
later, the results of a larger double-blinded, randomized controlled trial (DBRCT) 
led to contacts with EMEA for approval of memantine as a drug for the treatment of 
moderate to severe AD.3 Before approval, the EMEA requested a second randomized 
controlled trial which was conducted in 2000.4 Based on these two studies, meman-
tine was approved as an AD drug in Europe. Despite this registration, discussion 
concerning the clinical effectiveness of memantine is going on. In their 2007 report 
of ﬁ  nal appraisal determination, the UK National Institute for Health and Clinical 
Excellence (NICE) states “Memantine is not recommended as a treatment option for 
patients with moderately severe to severe Alzheimer’s disease except as part of well 
designed clinical studies.”5 This is however in contrast with the decision in many other 
countries, based on the same information, to reimburse the use of memantine. In this Neuropsychiatric Disease and Treatment 2009:5 238
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review, an oversight of pharmacodynamics and – kinetics of 
memantine is presented. Also data concerning efﬁ  cacy and 
safety in patients with AD are presented.
Pharmacodynamics
In the central nervous system (CNS), two types of receptors 
can be found: the ionotropic (excitatory) and metabotropic 
(excitatory or inhibitory) receptors. Ionotropic receptors are 
formed by multiple proteins that are coupled to an ionic chan-
nel. Following activation of this receptor, the ion channel will 
open, permitting cations or anions to enter or leave the cell. 
Metabotropic receptors are smaller and consist of only one 
protein that is coupled to a transducer protein. This transducer 
protein interacts with a primary effector inside the cell, which 
then interacts with a “second messenger”.6 Memantine is a 
glutamate antagonist, blocking the ionotropic NMDAR.7 
Glutamate is one of the major excitatory neurotransmitters in 
the brain and spinal cord and is considered of importance in 
learning processes. High concentrations of glutamate, leading 
to excessive NMDAR activity with increased inﬂ  ow of Ca2+ 
through the ion channel are thought to result in excitotoxic-
ity, a pathological process where neuronal injury or death 
occurs. Besides the NMDAR, three other glutamate receptors 
can be found: the ionotropic α-amino-3 hydroxy-5-methyl-
isoxazole-4-propionacid (AMPA) and kainacid receptors and 
a metabotropic glutamate receptor. The NMDAR consists 
of four subunits. The genes encoding these subunits, NR1 
(GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, and GRIN2D), 
and NR3 (GRIN3A and GRIN3B) were identiﬁ  ed just less 
than two decades ago. A functional NMDA receptor typically 
contains two NR1 and two NR2 subunits. Occasionally, a 
NR3 subunit is included. Glutamate can bind as an agonist 
to the NR2 subunits. For activation of the receptor, binding 
of co-agonist glycine (or occasionally D-serine) to the NR1 
subunits is also required. However, binding of these agonists 
is not sufﬁ  cient for functional opening of the ion channel. 
Opening is also voltage-dependent. Within the channel pore, 
a binding site for magnesium (Mg2+) is located. At resting 
membrane potential, Mg2+ binds to this site, blocking ion 
ﬂ  ow (especially Ca2+) through the channel. Since glutamate 
will also interact with postsynaptic AMPA receptors, Na+ 
inﬂ  ux through this channel will change membrane poten-
tial. When the membrane becomes depolarized, Mg2+ is 
expelled from the channel allowing passage of ions. Thus, 
both depolarization of the postsynaptic neuron and binding 
of agonists at NR1 and NR2 is required for ﬂ  ow of Ca2+ 
through the NMDAR channel. In AD, glutaminergic neu-
rons show overactivation, releasing more and continuously 
glutamate compared to non-AD state.7 Also, the NMDAR is 
more sensitive for glutaminergic stimulation. In these situa-
tions of overexcitation, Mg2+ is not capable of blocking the 
channel sufﬁ  ciently, leading to excess inﬂ  ow of Ca2+. This 
excess Ca2+ inﬂ  ux into cells activates a number of enzymes 
damaging cell structures (eg, cytoskeleton, membrane and 
DNA). Memantine blocks the open ion channel in a Mg2+ 
manner. After blockade of the channel, agonists will unbind 
from the receptors and the ion channel will close, trapping 
memantine inside. Memantine is called an “uncompetitive” 
blocker because it does not compete with agonists at binding 
sites. Other than Mg2+, memantine is less pronounced volt-
age dependent and therewith more capable of blocking the 
channel in case of overstimulation by excess glutamate. It will 
dissociate from the NMDAR channel upon depolarization 
in case of normal physiological activation, but will remain 
blocking the channel during moderate long-lasting depolar-
ization, as during chronic excitotoxic conditions. The concept 
of NMDA overstimulation leading to excitotoxicity is not 
AD speciﬁ  c. Also in many other neurological diseases (eg, 
multiple sclerosis, Parkinson’s disease, Huntington’s disease, 
epilepsy, acute stroke, neuropathic pain), NMDA overacti-
vation may contribute to pathophysiology.8 Besides having 
a role in direct neuronal death, hyperactive NMDARs have 
also been associated with neuroﬁ  brillary degeneration and 
tau toxicity in Alzheimer’s disease.9,10
Memantine was found to inhibit NMDARs with an IC50 
of approximately 1 mM, which is reached at the normal dosing 
range. At high concentrations (10–500 mM), memantine affects 
many CNS targets, including serotonin and dopamine uptake, 
nicotinic acetylcholine receptors (nAChRs), serotonin recep-
tors, sigma-1 receptors, and voltage-activated Na+ channels.7
Pharmacokinetics
The recommended starting dose of memantine is 5 mg once 
daily, with a target dose of 20 mg/day. The dose should be 
increased in 5 mg increments to 20 mg/day (10 mg twice daily), 
with a minimum of one week between each dose titration.11 
Recently, a once-daily formulation has become available. 
Following oral ingestion, memantine is almost completely 
absorbed. Food has no effect on its absorption. Since it is not 
subject to major metabolism in the liver, plasma levels are sim-
ilar to the given dose. Peak plasma levels are reached within 
5–6 hours (t-max). Peak plasma concentration (Cmax) follow-
ing a single 20 mg oral dose of memantine ranges between 
22 and 46 ng/mL. Steady state levels are reached around day 
11 with accumulation in plasma resulting in approximately 
3 to 4 times Cmax compared with that following a single Neuropsychiatric Disease and Treatment 2009:5 239
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dose. Memantine is protein bound for approximately 45%. It 
has a distribution volume of 9 L/kg, indication major tissue 
distribution. The terminal half-life is 60 to 100 hours. Since 
aging is associated with polypharmacy, potential drug-drug 
interactions may be important in drug selection. The risk of 
interactions of memantine with other drugs is low. It is not 
a substrate for phase I metabolization (cytochrome P-450). 
No inﬂ  uence of known inducers or inhibitors of individual 
sub-families of CYP450 (CYP 2A6, CYP2C9, CYP 2D6, 
CYP 2E1, CYP 3A, CYP 1A2) has been found in interaction 
studies. Especially important, no interactions with cholin-
esterase inhibitors have been found.12–14 A small proportion 
of memantine is metabolized through a phase II reaction 
in which multiple polar metabolites are formed as a result 
of conjugation or hydroxylation (memantine N-gludantan 
conjugate, 4-and 6-hydroxy memantine and 1-nitroso-deami-
nated memantine). However, none of these metabolites show 
clinically relevant effects. Since moderate hepatic impairment 
(Child-Pugh A and Child-Pugh B) does not alter the phar-
macokinetics of memantine, no dosage adjustment is needed 
in these stages. No data on the use of memantine in patients 
with severe hepatic impairment are available. Memantine 
clearance is mainly dependent on renal function. Renal excre-
tion accounts for 65% to 90% of the clearance of unchanged 
memantine. The remaining part can be found in bile and feces. 
The formed metabolites are mainly excreted by the kidney. 
Renal clearance involves active tubular secretion moderated 
by pH-dependent tubular reabsorption. In patients with a renal 
clearance between 30 and 50 mL/min/1.73 m2, exposure is 
about 60% increased. No dose reduction is advised in this 
range. Dose titration in these patients should be performed 
cautiously and based on side effects. In patients with a renal 
clearance between 10 and 30 mL/min/1.73 m2, exposure is 
doubled compared to controls.15 The maximum daily dose in 
these patients should be set at 5 mg twice-daily. Since renal 
function may decline as result of newly prescribed medication 
(eg, non-steroid anti-inﬂ  ammatory drugs, diuretics, ACE 
inhibition), side effects of memantine may develop in patients 
who have used memantine for some period. The pharmacoki-
netics of memantine can be signiﬁ  cantly affected by high or 
low urine pH values.16 Alkaline urine pH results in reduced 
renal excretion and renal clearance, while acidic urine pH may 
result in increased renal clearance of memantine.
Efﬁ  cacy of memantine in AD
Endpoints in AD trials with memantine
The effects of memantine in AD have been studied in both 
patients with mild to moderate AD (Mini Mental State 
Examination [MMSE]: 14–24) and patients with moderate 
to severe AD (MMSE   14). Primary endpoints in AD 
trials required by most regulatory authorities for granting a 
drug license are ‘global functioning’ and ‘activities of daily 
living’ (ADL). In patients with mild to moderate AD, cog-
nition is also considered a compulsory primary endpoint.17 
The effects of drugs on behavioral symptoms are considered 
secondary outcomes.
Assessment of global functioning18
Until now, this is preferably measured with the Clinician’s 
Interview-Based Impression of Change Plus Caregiver 
Input (CIBIC-Plus) or the Clinical Dementia Rating (CDR). 
The CIBIC-Plus measures overall levels of cognition, 
function, and behavior through the use of patient interviews 
along with caregiver observations. It is scored as a 7-point 
categorical rating, ranging from a score of 1 (indicating 
“markedly improved”) to a score of 7 (indicating “marked 
worsening”). The CDR is a 5-point scale used to character-
ize six domains of cognitive and functional performance 
applicable to Alzheimer disease and related dementias. 
The necessary information to make each rating is obtained 
through a semi-structured interview of the patient and a 
reliable informant. The Global Deterioration Scale (GDS) 
separates the course of dementia into 7 stages. The Functional 
Assessment Staging Tool (FAST) separates deterioration 
into 16 stages.
Assessment of ADL
In most studies, ADL is assessed with the Alzheimer’s Disease 
Cooperative Study (ADCS) ADL scale. The ADCS-ADL 
is administered as an interview with the caregiver and 
is focused on the performance of each ADL during the 
prior 4 weeks.6 Possible scores range from 0 to 54, a higher 
score indicating better ADL function.21 In severe AD, the 
Behavioral Rating Scale for Geriatric Patients (BGP)–Care 
Dependency subscale can also be used.22 The BGP consists of 
35 items (scored 0, 1, or 2 by the rater) assessing observable 
aspects of cognition, function and behavior.16 A higher score 
reﬂ  ects worse function. The BGP care dependency subscale 
reﬂ  ects cognitive and functional characteristics associated 
with increased need for care.
Assessment of cognition
In moderate to severe AD, cognition is often assessed with 
the Severe Impairment Battery (SIB), which, compared 
to the easier to use MMSE, is more appropriate for the 
assessment of cognition in severe AD patients (MMSE Neuropsychiatric Disease and Treatment 2009:5 240
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below 12 points). The SIB is a 100-point, 40 item test. Higher 
scores indicate better functioning. The AD Cooperative Study 
group reported that for untreated patients with AD with 
MMSE scores of 5 to 9, the mean deterioration rate on the 
SIB was roughly 3.19 per month and for untreated patients 
with AD with MMSE scores of 10 to 15, the rate of change 
was 2.08 per month.19
In mild to moderate AD, cognition is mostly assessed 
with the Alzheimer’s Disease Assessment Scale-Cognitive 
subscale (ADAS-Cog).20 The ADAS-Cog measures sev-
eral cognitive domains, including memory, language and 
praxis. Total scores range from 0 to 70, with higher scores 
indicating greater cognitive impairment. In general, regu-
latory authorities recognize a four-point change on the 
ADAS-Cog at 6 months as indicating a clinically important 
difference.
Assessment of behavior
The Neuropsychiatric Inventory (NPI) assesses behaviors 
common in dementia including delusions, hallucinations, 
agitation/aggression, dysphoria/depression, anxiety, eupho-
ria, disinhibition, irritability, aberrant motor behavior, 
alterations in appetite, apathy, and changes in nighttime 
behavior.23 The scores are based on interviews with care-
givers and assess behaviors that were present in the last 
4 weeks. Frequency and severity scores are elicited from 
the caregiver with anchored ratings, and the total score 
for each domain is the product of the severity score (1–3) 
multiplied by the frequency score (1–4). The total score for 
the NPI is the sum of the individual domain scores, ranging 
from 0 to 144. The NPI also includes a caregiver distress 
rating. Caregivers rate their own distress associated with 
each behavior on an anchored scale of 0 to 5. The total NPI 
distress score is the sum of the distress scores associated 
with each behavioral domain and can range from 0 to 60. 
For both scales, higher scores reﬂ  ect worse symptoms or 
distress
Double blinded, randomized controlled 
trials in moderate to severe AD (Table 1)
Four double-blinded randomized controlled trials (DBRCT) 
comparing the effects of memantine with placebo in patients 
with moderate to severe AD have been published.3,4,24,25
The ﬁ  rst trial was the study by Winblad et al who stud-
ied the effect of memantine 10 mg/d during a follow-up of 
3 months.3 The patient population studied in this study con-
tained both patients with AD (n = 79) and vascular dementia 
(VAD [n = 87]). Important inclusion criteria were inpatients 
aged between 60 and 80 years with a MMSE score   10, GDS 
stages 5 to 7. Since no brain imaging was done, the diagnosis 
AD or VAD was further based on the Haschinsky Ischemic 
Score (HIS). A HIS   5 was associated with probable AD. 
Primary endpoints were the 7-point Clinical Global Impres-
sion of Change (CGI-C) scale and the BGP-care dependency 
subscale. The Clinical Global Impression of Severity of 
illness (CGI-S) scale and the BGP total score together with 
the D-scale (designed to evaluate behavioral and functional 
activities in demented patients) were used as secondary 
efficacy variables. In the AD-group, more patients on 
memantine improved on the CGI-C compared with placebo 
(73% vs  42% p   0.001). Also on the BGP care dependency 
subscale, memantine treated AD patients performed better. 
In the memantine group, the mean BGP care dependency 
sub score (± standard deviation) fell with 3.5 ± 12.5 points 
from baseline to 12 weeks compared to 1.6 ± 9.2 points in 
the placebo group. In a responder analysis for the combined 
AD and VAD group, using combined response criteria 
(improvement in CGI-C and  15% improvement in BGP), 
response was observed in 61% of memantine treated patients 
compared with 26% of placebo-treated patients. Among the 
secondary parameters examined in this AD/VAD group, a 
statistically signiﬁ  cant beneﬁ  t for memantine compared with 
placebo was also observed in the BGP total score. Memantine 
patients also performed better than placebo on all items of 
the D-scale.
Reisberg et al studied the effects of memantine (20 mg/d) 
in 181 patients with moderate to severe AD (MRZ-9605).4 
In the ITT-LOCF analysis at the end of the 26 weeks follow 
up period, memantine treated patients had statistically 
signiﬁ  cant better scores on the ADL and cognitive endpoints 
(ADCS-ADL score, p = 0.02; SIB p   0.001) compared to pla-
cebo. Borderline signiﬁ  cance was found for global functioning 
(CIBIC-plus score; p = 0.06). When analysis was based on 
observed cases, this primary endpoint also reached statistical 
signiﬁ  cance. A separate analysis was performed comparing 
the percentage of responders in both treatment groups. Two 
responder deﬁ  nitions were used. In the ﬁ  rst deﬁ  nition, a 
responder was deﬁ  ned as ‘each patient that improved or had 
no deterioration on the CIBIC-Plus, ADCS-ADL and SIB’. 
In the second analysis a responder was less strictly deﬁ  ned 
as ‘each patient that improved or had no deterioration on the 
CIBIC-Plus and who had improved or had no deterioration 
on either the ADCS-ADL or the SIB’. For the ﬁ  rst responder 
analysis (that was left out of the publication) there was no 
statistically signiﬁ  cant difference between treatment groups 
(p = 0.17); 11% of memantine and 6% of placebo group were Neuropsychiatric Disease and Treatment 2009:5 241
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responders. In the second analysis 29% of the memantine and 
10% of the placebo group responded (p   0.001). On the 
secondary endpoints MMSE, FAST and GDS, memantine 
treated patients did better only on the FAST. This study also 
assessed neuropsychiatric functioning. Unfortunately, no sign 
of positive effect of memantine on neuropsychiatric symptoms 
could be found in both LOCF and OC analysis.
For this study, two post-hoc analyses were published.26,27 
An analysis of resource utilization and a cost analysis showed 
that less caregiver time was needed for patients receiving 
memantine than for those receiving placebo (difference 
51.5 hours per month; 95% CI −95.27, −7.17; p = 0.02).26 
Analysis of residential status also favored memantine: time 
to institutionalization (p = 0.052) and institutionalization at 
week 28 (p = 0.04). However, absolute numbers were low. 
Only one patient in the memantine group and 5 patients 
in the placebo group were institutionalized. Total costs 
from a societal perspective were lower in the memantine 
Table 1 Published double-blinded randomized controlled trials with memantine
Study MMSE Number of patients 
(intervention/placebo)
Follow-up 
(weeks)
Age 
(mean)
Outcomes (ITT -LOCF)
Winblad (1999)3  10 82 (41 AD)/84 (38 AD) 12 68 male CGI-C 0.002
74 female BGP-care dependence 0.003
BGP-total 0.007
Reisberg (2003)4 MRZ 9605 3–14 126/126 28 75 ADCS-ADL 0.02
CIBIC-plus 0.06
SIB   0.001
MMSE ns
FAST 0.02
GDS ns
NPI ns
van Dyck (2007)24 MEM-MD-01 5–14 178/172 24 78 SIB ns
ADCS-ADL ns
CIBIC-plus ns
NPI ns
FAST 0.09
BGP-total ns
BGP-care dependence 0.08
Tariot (2004)25 MEM-MD-02 5–14 203/201 24 75 SIB   0.01
ADCS-ADL19 0.03
CIBIC-Plus 0.03
NPI 0.002
BGP-care dependence 0.001
Peskind (2006)33 MEM-MD-10 10–22 201/202 24 78 ADAS-cog 0.003
CIBIC-plus 0.004
NPI 0.01
ADCS-ADL ns
Bakchine (2008)35 11–23 318/152 24 74 ADAS-cog ns
CIBIC-plus ns
NPI ns
ADCS-ADL ns
Porsteinsson (2008)36 MEM-MD-12 10–22 178/172 24 75 ADAS-cog ns
CIBIC-plus ns
NPI ns
ADCS-ADL ns
Notes: Primary outcomes are indicated in bold.Neuropsychiatric Disease and Treatment 2009:5 242
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group (p = 0.01). The second post-hoc analysis studied the 
effect of memantine on activities of daily living.27 For this 
analysis, based on ADCS-ADL scores, two ADL subtypes 
were created and scored. Based on the combination of these 
scores, patients were classiﬁ  ed as autonomous or dependent. 
Further analysis showed that a patient treated with memantine 
was more than 3 times as likely (OR = 3.03; 95% CI = [1.38, 
6.66]) to be autonomous after 6 months.
Finally, the study was followed by a 24-week open-label 
extension study.28 In this extension study, all patients received 
memantine in a maintenance dose of 20 mg/d. Blinding 
for treatment during the preceding double-blind 28-week 
period was maintained. Of 181 patients who completed the 
double-blind phase, 80 patients treated with placebo and 
95 patients treated with memantine opted to enter the open-
label extension. For patients in the former placebo group, 
switching to memantine, treatment resulted in a signiﬁ  cantly 
slower rate of decline on the ADCS-ADL, the CIBIC-Plus 
and the SIB compared with the mean rate of decline during 
the double-blind placebo period.
In the third study by van Dyck et al (MEM-MD-01), 
patients with probable AD were assigned to memantine 
(20 mg/d) or placebo during a 24-week follow-up period.24 
Study population and chosen endpoints were largely compa-
rable with the Reisberg study. Surprisingly, and in contrast 
with the outcomes of the Reisberg study, for none of the 
primary and secondary endpoints a beneﬁ  t for memantine 
was found at 24 weeks. At weeks 12 and 18, a statistically sig-
niﬁ  cant advantage on the SIB and CIBIC-Plus was observed 
for memantine in the LOCF-analysis, but this disappeared at 
week 24. Several post-hoc analyses, using different statistical 
techniques, were performed in order to explain the difference 
in outcomes with earlier studies. Despite these analyses, no 
explanation could be found, suggesting that other unexplained 
factors may be involved.24
The results of the fourth DBRCT were published by 
Tariot et al (MEM-MD-02).25 The study design and chosen efﬁ  -
cacy parameters used in this study are also largely comparable 
with the Reisberg and van Dyck studies except for one point. 
The use of cholinesterase inhibitors was forbidden in the earlier 
studies, while in this study all patients had to be on ongoing 
cholinesterase inhibitor therapy with donepezil for more than 
6 months before entrance into the trial and at a stable dose 
(5–10 mg/d) for at least 3 months. The memantine treated group 
showed favorable outcomes for all predeﬁ  ned efﬁ  cacy param-
eters. On the CIBIC-Plus, 55% of the memantine group was 
rated as improved or unchanged vs 45% of the placebo group 
at end point. This publication was followed by four publications 
describing post-hoc analyses on over-all responders and most 
individual outcomes.29–32 The post-hoc responder analysis 
showed the response rates (%) for stabilization on individual 
outcomes ([memantine: placebo]: SIB 62.6: 51.6, ADCS-
ADL19 45.9: 35.5, CIBIC-Plus 55.2: 44.1 and NPI 60.8: 
48). Although all differences were statically signiﬁ  cant and 
numbers needed to treat (NNT) were around 9, the large 
placebo effect is remarkable.29 The effect of memantine on 
cognitive performance was further assessed in this analysis 
by creating 4 response categories relative to basement on the 
SIB (improvement  0,  4,  8 and  12 points). NNT for 
these categories ranged from 9 to 20. The calculated absolute 
risk reduction between memantine and placebo was signiﬁ  -
cant for the broadest increment ( 0-point improvement) and 
the  8-point improvement increment. Deﬁ  nitions of response 
that required simultaneous stabilization on multiple outcome 
measures again favored memantine treatment for 6 out 
of 10 combinatorial response deﬁ  nitions. The positive effects 
of memantine on the secondary outcome NPI triggered another 
post-hoc exploratory analysis by Cummings et al.30 Mean 
baseline NPI scores of 13.8 for the placebo group and 13.7 
for the memantine group indicate that most patients in the trial 
had low to moderate levels of psychopathology at entry. At 
week 24, the placebo group continued to deteriorate behavior-
ally whereas the memantine group returned approximately to 
baseline (p = 0.002). Memantine treated patients scored better 
on the NPI items: agitation/aggression and appetite/eating 
changes. No behaviors worsened signiﬁ  cantly on memantine 
compared with placebo. Schmitt et al performed an explor-
atory analysis on the cognitive response (SIB).31 The effects 
of memantine on individual items of the SIB, subscale per-
formance, and 3 post-hoc-derived aggregate subscales were 
investigated. The SIB subscale analysis showed statistically 
signiﬁ  cantly greater effects of memantine than placebo on 
memory, language, and praxis. Finally, Feldman et al focused 
on ADL effect of memantine using ‘observed case’ (OC) and 
‘mixed model repeated measures’ (MMRM) approaches.32 
Three response categories relative to basement on the ADCS-
ADL19 were created (improvement  0,  4 and  8 points). 
Numbers needed to treat for these categories ranged from 
10 to 23. An item analysis revealed statistically signiﬁ  cant 
beneﬁ  ts of memantine on grooming, toileting, conversing, 
watching television, and being left alone.
Double blinded, randomized controlled 
trials in mild to moderate AD
In patients with mild to moderate AD, 3 DBRCT have been 
published.Neuropsychiatric Disease and Treatment 2009:5 243
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Peskind at al studied the effect of memantine 20 mg/d for 
24 weeks in 403 US outpatients with AD and MMSE scores 
of 10 to 22 (MEM-MD-10).33 Patients were not allowed to 
use cholinesterase inhibitors. The study showed a statistically 
signiﬁ  cant difference using ITT-LOCF analysis in favor of the 
memantine treated group on both primary outcomes cognition 
(assessed by ADAS-Cog) and global functioning (assessed 
by CIBIC-Plus). At 24 weeks, memantine treated patients 
had a statistically signiﬁ  cant difference on the ADAS-Cog 
of −1.9 points compared to placebo. On the CIBIC-Plus, 
67.3% of memantine treated patients were either stabilized or 
improved compared with 50.8% of placebo patients. No posi-
tive effects of memantine were found on ADL. Memantine 
treated patients showed better scores on the NPI compared to 
placebo group (−3.5 point corrected mean treatment differ-
ence). A remarkable outcome in this study was that in the OC 
analysis, no signiﬁ  cant difference between treatment groups 
could be established for ADAS-Cog and NPI.
Pomara et al performed a post-hoc analysis on these data, 
examining the effects of memantine on individual items and 
sub-scales of the ADAS-Cog.34 Memantine treatment showed 
beneﬁ  ts over placebo on subscales language (3 out of 4 items) 
and memory (2 out of 5 items) but not on praxis.
Bakchine and Loft performed a 24-week DBRCT with 
memantine 20 mg/d in 12 European countries.35 Concomitant 
use of cholinesterase inhibitors was not allowed. Except for a 
different randomization ratio (2:1), the study design and chosen 
outcome variables were largely comparable with the US study 
by Peskind. For both ADAS-Cog and CIBIC-Plus, a statisti-
cally signiﬁ  cant beneﬁ  t from memantine could be established 
on 12 and 18 weeks, but not on the pre-determined endpoint 
of 24 weeks. For both ADL and neuropsychiatric problems 
no beneﬁ  t of memantine was found on every time point. The 
authors believe that these unexpected results may be attributed 
to the unexpected improvement in the placebo group on both 
ADAS-Cog and CIBIC in the last weeks of the study.
In the study by Porsteinsson et al the efﬁ  cacy and safety of 
memantine 20 mg/d was studied in patients with mild to mod-
erate AD receiving a stable dose of a cholinesterase inhibitor 
(donepezil, rivastigmine, galantamine).36 Outcome measures 
were identical to both other studies in mild to moderate AD. At 
the end of the 24-week evaluation, this study also showed no 
statistically signiﬁ  cant differences between the memantine- and 
placebo group on primary and secondary outcome measures.
Post-hoc pooled data analyses
It must be concluded that the statistical beneﬁ  t of memantine 
on cognition, global functioning and ADL is not found in all 
studies in moderate to severe AD. Trials in mild to moderate 
AD even show worse data. Since small effects in individual 
studies may be detected in larger cohorts, mainly by smaller 
conﬁ  dence intervals, several reports have been published in 
which the results of the DBRCT are pooled.37–42 Although 
these meta-analyses differ slightly in methodology, basically 
all these studies show small but statistically relevant differ-
ences in favor of memantine on cognition and global func-
tioning in patients with moderate to severe AD. However, 
meta-analyses may differ in quality and outcomes should 
be looked at with caution. Most meta-analyses may include 
both studies in mild to moderate and moderate to severe AD, 
which clinically does not make sense. Also, combining of 
data from trials with and without the use of cholinesterase 
inhibitors is not logical.
As is shown in Table 1, memantine showed a statistically 
signiﬁ  cant effect on the NPI in only 2 studies. Maidment et al 
pooled NPI data from 5 studies4,24,25,33,34,36 Using a random 
effects model, the total difference in mean NPI value was 
small but statistically signiﬁ  cant (−1.99; 95% Cl −0.08 to 
−3.91; p = 0.041). The negative results from the study by 
Backchine were not included in this analysis. Given the fact 
that the upper-limit of the conﬁ  dence interval in the pooled 
analysis almost includes zero, it is reasonable to assume 
that inclusion of this study would have shifted the conﬁ  -
dence intervals in which case statistical signiﬁ  cance could 
have been lost. Wilcock et al performed another analyses 
on behavioral effects.44 They pooled the data from 3 stud-
ies4,24,25 in moderate to severe AD. The effects of meman-
tine and placebo now were analyzed in the 593 patients 
who scored at baseline on one the NPI items agitation/
aggression, delusions or hallucinations. At 24 weeks, a 
signiﬁ  cant proportion of memantine treated patients showed 
improvement on this symptom cluster compared to placebo 
(58% vs  44.8%; p = 0.008). On the individual items, only for 
the item agitation/aggression a statically higher proportion of 
responders was found in the memantine treated group (61 vs 
45%; p   0.01). Of those patients who were asymptomatic 
at baseline, signiﬁ  cantly fewer memantine treated patients 
went on to develop these symptoms (24.2 vs 37%; p = 0.007). 
The possible effects of memantine on neuropsychiatric 
functioning are indirectly supported by data from the French 
national Health Care Database. In a sample of 4600 meman-
tine treated patients psychotropic drug use before and after 
onset of memantine was analyzed. Before memantine onset, 
an increasing trend for psychotropic drug use could be seen. 
After memantine initiation, psychotropic drug use stabilized 
(but did not decrease).45Neuropsychiatric Disease and Treatment 2009:5 244
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Economic effects
Many studies have been presented focusing on cost-
effectiveness of memantine.46–53
These studies are very difﬁ  cult to interpret or compare to 
other cost-effectiveness studies. Although cost-effectiveness 
for memantine is claimed in these studies, data are difﬁ  cult 
to interpret since used models are not always presented in a 
clear way and assumptions made to build the models can be 
discussed.54 A large problem with these analyses is the lack 
of consensus how to measure costs and how to value ben-
eﬁ  ts. For instance, in the cost-effectiveness study by Wimo 
et al caregiver time was valued at US$9.18 to $23.65/hour, 
depending on factors like age and gender of the caregiver, 
whereas in a study of donepezil in moderate to severe AD 
this was valued at only US$4.6/hour.26,55 A higher valuation 
of items that are positively inﬂ  uenced by memantine at equal 
costs automatically increases the beneﬁ  ts of the drug. Also, 
the found cost-effectiveness calculations are mainly based 
on the results of positive trials. It must be noted that the 
last three published trials that failed to show these positive 
effects are often not used for modeling. The NICE Committee 
discussed cost-effectiveness based on information provided 
by the registration holders. This also included non-public and 
non-published information. They concluded that, on the basis 
of current evidence on clinical effectiveness, memantine 
could not reasonably be considered a cost-effective therapy 
for moderately severe to severe Alzheimer’s disease.5 So, 
with contradicting views on how to measure effectiveness 
and costs, a deﬁ  nite valuation of the cost-effectiveness of 
memantine will be difﬁ  cult. Determining effectiveness in 
terms of utilities like Quality Adjusted Life Years (QALYs) 
is even more difﬁ  cult since there is a lack of well-validated 
or uniformly accepted measures of quality of life in dementia. 
The few data on current QALY estimates for dementia have 
been subject to widely different interpretations.56
Safety and tolerability
Recently, Farlow et al published pooled data concerning tol-
erability and safety from data from trial data.57 In this analysis, 
not only published data but also data on ﬁ  le from manufactur-
ers (Forest Laboratories, Inc., Merz Pharmaceuticals GmbH 
and H. Lundbeck A/S) were used. It was concluded that the 
tolerability and safety of memantine in patients with AD is 
almost indistinguishable from that of placebo. However, these 
data provided and published by the manufacturers themselves 
may be biased. Less changes of bias can be expected in safety 
data presented by Registration authorities (eg, EMEA and 
FDA). For the purpose of monitoring the safety aspects of 
registered drugs, these authorities can use several sources of 
information. Firstly, data from all trials are used. Furthermore, 
following registration, registration holders must provide 
periodic data concerning serious side effects that occurred 
during the post registration phase, the so-called Periodic 
Safety Update Reports (PSURs). These PSURs are not public. 
Because of this non-public nature of part of the safety data, 
product characteristics provided by registration authorities 
are the most complete source of information. A third source 
for safety data can be found in the spontaneous reports from 
patients and health care providers. These data that are col-
lected by national organizations are grouped in the WHO 
Collaborating Centre for International Drug Monitoring. 
The Summary of Product Characteristics (SPC) as provided 
by the EMEA summarizes adverse drug reactions (ADRs) 
found in clinical trials in mild to severe dementia. In 1784 
patients treated with Memantine and 1595 patients treated 
with placebo, the overall incidence rate of adverse reactions 
with memantine did not differ from those with placebo; the 
adverse events were usually mild to moderate in severity. 
The most frequently occurring adverse events with a higher 
incidence in the memantine group than in the placebo group 
were dizziness (6.3% vs 5.6%, respectively), headache (5.2% 
vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 
2.2%) and hypertension (4.1% vs 2.8%).58 Reported adverse 
drug reactions from this SPC are listed in Table 2.
With the exception of the Winblad study, all presented 
studies studied the safety and efﬁ  cacy of memantine 20 mg/d, 
given as 10 mg bid. The safety and tolerability of a different dos-
ing schedule has been studied in a 28-week open label extension 
study (MEM-MB-11AB) to the study by Peskind. In this study, 
the safety and tolerability of memantine 20 mg once-daily was 
compared with standard dose of 10 mg twice daily.59 Individual 
adverse events in the once-daily dosage regimen were similar 
with those in the twice-daily regimen (perhaps with slightly 
more agitation and somnolence in the once-daily regimen), 
indicating that once-daily dosing is safe and well tolerated.
Jones et al studied 3 dosing schedules (20 mg once daily 
with a 3-step up-titration, 20 mg once daily with a 1-step up-
titration and 10 mg twice daily with a 3-step up-titration) in a 
12-week DBRCT in 78 patients.60 Given the small numbers in 
each group, solid conclusions can not be drawn. The authors 
conclude that once-daily dosing and twice-daily dosing of 
memantine are similar in terms of safety and tolerability.
Conclusions
Randomized controlled trials of memantine in AD patients 
show very different outcomes. With some caution, it may Neuropsychiatric Disease and Treatment 2009:5 245
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be concluded that possible effects are larger in patients 
with moderate to severe AD than in patients with mild 
to moderate AD. Two out of 3 trials in the MMSE range 
10 to 22 were negative at the end of the predeﬁ  ned period 
of 26 weeks on all outcomes. As cholinesterase inhibitor 
therapy is almost standard in mild to moderate AD, studies 
comparing memantine treatment with placebo must be 
considered clinically less relevant. The only study describing 
the effects of memantine in patients with mild to moderate 
AD on stable cholinesterase inhibitor therapy fails to show 
a positive effect on every outcome. However, in moderate 
to severe AD, addition of memantine to a donepezil may be 
useful. This potential positive effect of combination therapy 
is supported by a retrospective analysis of 382 AD patients 
that were treated in a Memory Disorders Unit with a mean 
follow-up of 30 months. Combination therapy was more 
effective in slowing cognitive and functional decline than 
therapy with ChEIs alone. These effects were sustained for 
the whole follow-up period.61
For patients with a MMSE above 14, data do not support 
the prescription of memantine. The meta-analysis by Doody 
et al show that, half of the patients in the moderate to severe 
trials tended toward the moderate and most patients in mild 
to moderate trials tended toward the more mild range. Since 
effect sizes tended to be larger in the moderate to severe 
than in the mild to moderate trials, there is a relative lack 
of evidence for memantine’s efﬁ  cacy at the more mild and 
severe ends of the MMSE range.41 So available evidence 
points towards statistical signiﬁ  cant effects of memantine 
in patients with an MMSE   14. Since both studied patient 
groups show an overlap in the MMSE range of 10 to 14 it 
is difﬁ  cult to draw conclusions on the effect of memantine 
in this range. It would have been clearer if outcomes had 
been pooled for smaller, non-overlapping MMSE categories. 
But, even in the group with low MMSE scores, the found 
effects of memantine on cognition, global functioning, 
ADL and neuropsychiatric symptoms are small. Do these 
found efﬁ  cacy data, also mean clinical relevant effective-
ness? A clinically relevant treatment can be deﬁ  ned as one 
in which the change is both relevant and important to the 
patient or caregiver. It is difﬁ  cult to create cut-off scores for 
relevance on individual assessment scales. As will be clear 
from presented studies, many study groups create new deﬁ  -
nitions for clinical relevance in their post-hoc analysis. But, 
accepting clinical effectiveness based on post-hoc analyses 
is incorrect. Post-hoc analyses must be the basis for further 
research, not the basis for solid conclusions. The effects of 
shifting of criteria for response are shown in the Reisberg 
study. In the responder analyses, strict response criteria 
(stabilization on all three primary outcomes) presented in 
the European Public Assessment Report (EPAR), resulted 
in non-signiﬁ  cant results. Only 11% of the memantine group 
were responders.12 With a less strict response deﬁ  nition 
(stabilization on 2 out of 3 primary outcomes), presented in 
Table 2 Adverse drug reactions of memantine
Nervous system disorders Common Dizziness
Uncommon Gait abnormal
Very rare Seizures
Gastrointestinal disorders Common Constipation
Uncommon Vomiting
Not known Pancreatitisa
Infections Uncommon Fungal infections
Vascular disorders Common Hypertension
Uncommon Venous thrombosis/thromboembolism
General disorders and administration site 
conditions
Common
Uncommon
Headache
Fatigue
Psychiatric disorders Common Somnolence
Uncommon Confusion
Uncommon Hallucinationsb
Not known Psychotic reactionsa
Notes:   Very common ( 1/10), common ( 1/100 to  1/10), uncommon ( 1/1,000 to  1/100), rare ( 1/10,000 to  1/1,000), very rare ( 1/10,000), not known (cannot 
be estimated from the available data).
aIsolated cases reported in post-marketing experience.
bHallucinations have mainly been observed in patients with severe Alzheimer´s disease.Neuropsychiatric Disease and Treatment 2009:5 246
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the published manuscript, 29% of the memantine and 10% 
of the placebo group responded.4,12
Another problem is that goals for treatment will vary with 
disease stage. In early stages, the aim is to improve cogni-
tion and slow progression of disease. In the mid-stages of 
the disease, the emphasis is on preserving function (that is, 
ADLs) and delaying institutionalization. In the late stages in 
which many patients will be institutionalized, the emphasis 
moves toward management of difﬁ  cult behaviors.
So, it must be concluded that memantine is a relatively 
safe drug with few side effects and neglectable risk of 
drug-drug interactions but only small clinical relevant effects 
on cognition, global functioning and ADL, mainly in patients 
with moderate AD. Furthermore, it may have some effects 
on neuropsychiatric functioning (especially on agitation/
aggression, delusions or hallucinations), but more studies 
on this topic are needed for solid conclusions.
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